United Therapeutics Corp (UTHR) 89.51 $UTHR
United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 12:20PM CDT
Lower costs and higher revenues helped United Therapeutics (UTHR) deliver better-than-expected earnings.
Why Neptune Technologies (NEPT) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:42AM CDT
Neptune Technologies has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off.
United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:37AM CDT
United Therapeutics Corporation (UTHR) was a big mover last session, as the company saw its shares rise more than 8% on the day
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 8.10% Gain
Comtex SmarTrend(R) - Tue Jul 29, 5:03PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $94.00 to a high of $102.27. Yesterday, the shares gained 8.1%, which took the trading range above the 3-day high of $94.67 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
United Therapeutics Corporation Reports Second Quarter 2014 Financial Results
PR Newswire - Tue Jul 29, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2014.
United Therapeutics Corporation To Announce Second Quarter 2014 Financial Results Before Market Open On Tuesday, July 29, 2014
PR Newswire - Tue Jul 22, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its second quarter 2014 financial results before market open on Tuesday, July 29, 2014.
Supernus Up on Non-Dilutive Royalty Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 3:43PM CDT
Supernus Pharmaceuticals, Inc.'s (SUPN) inked a non-dilutive royalty deal worth $30 million with HealthCare Royalty Partners.
Pluristem Initiates Trial in South Korea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 5:00PM CDT
Pluristem Therapeutics Inc. (PSTI) announced that it has initiated a phase II trial in South Korea to evaluate PLacental eXpanded cells for the treatment of intermittent claudication.
Supernus to Receive $30 Million in Non-Dilutive Royalty Deal
GlobeNewswire - Tue Jul 08, 6:30AM CDT
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced the execution of a royalty acquisition agreement ("Agreement"
with HealthCare Royalty Partners ("HC Royalty" . Per the Agreement, HC Royalty will make a $30 million cash payment to Supernus in consideration for acquiring from Supernus certain royalty and milestone rights related to the commercialization of Orenitram(TM) (treprostinil) Extended-Release Tablets by Supernus' partner United Therapeutics Corporation. Supernus will retain full ownership of the Royalty Rights after a certain threshold has been reached per the terms of the Agreement.
Clinical Trial Update, Recommendations for Approval, Share Repurchase Programs, and Closing of Public Offering - Analyst Notes on Medtronic, Regeneron, Lilly, United Therapeutics and Receptos
PR Newswire - Wed Jul 02, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Eli Lilly and Company (NYSE: LLY), United Therapeutics Corporation (NASDAQ: UTHR) and Receptos Inc. (NASDAQ: RCPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4341-100free.
After Yesterday's Rally of 1.61% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jun 27, 4:57PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $88.05 to a high of $91.30. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $90.30 on volume of 778,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of United Therapeutics to Potentially Pullback after Yesterday's 1.61% Rise
Comtex SmarTrend(R) - Fri Jun 27, 4:56PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $88.05 to a high of $91.30. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $90.30 on volume of 778,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Today's Top Biotech Stocks: Bristol-Myers Squibb, United Therapeutics and Vertex Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Fri Jun 27, 8:11AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb , United Therapeutics and Vertex Pharmaceuticals . Bristol-Myers is a fountain of good news this morning Shares of...
United Therapeutics Announces Additional $500 Million Share Repurchase Program
PR Newswire - Fri Jun 27, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to an additional $500 million of the company's common stock. This program will become effective on August 1, 2014, and will remain open for up to one year. Purchases may be made in the open market or in privately negotiated transactions from time to time as determined by United Therapeutics' management and in accordance with the requirements of the U.S. Securities and Exchange Commission.
Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global
Health Care Sector Stocks Technical Analysis -- Research on United Therapeutics, IsoRay, Bruker, and Affymetrix
PR Newswire - Mon Jun 23, 6:50AM CDT
On Friday, June 20, 2014, the NASDAQ Composite ended at 4,368.04, up 0.20%, the Dow Jones Industrial Average finished the session at 16,947.08, up 0.15% and the S&P 500 closed at 1,962.87, up 0.17%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.84% higher at 702.66, and the index has advanced 3.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: United Therapeutics Corp. (NASDAQ: UTHR), IsoRay Inc. (NYSE MKT: ISR), Bruker Corp. (NASDAQ: BRKR) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on UTHR, ISR, BRKR and AFFX can be downloaded upon signing up at:
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into United Therapeutics Corporation Regarding Possible Breaches of Fiduciary Duty
Business Wire - Thu Jun 19, 12:18PM CDT
Levi & Korsinsky, LLP is investigating United Therapeutics Corporation (Nasdaq:UTHR) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company.
After Yesterday's Decline of 4.59%, United Therapeutics Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 17, 4:30PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $86.07 to a high of $90.55. Yesterday, the shares fell 4.6%, which took the trading range below the 3-day low of $89.24 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Falls 4.59% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 17, 4:30PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $86.07 to a high of $90.55. Yesterday, the shares fell 4.6%, which took the trading range below the 3-day low of $89.24 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 12:20PM CDT
Lower costs and higher revenues helped United Therapeutics (UTHR) deliver better-than-expected earnings.
Why Neptune Technologies (NEPT) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:42AM CDT
Neptune Technologies has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off.
United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:37AM CDT
United Therapeutics Corporation (UTHR) was a big mover last session, as the company saw its shares rise more than 8% on the day
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 8.10% Gain
Comtex SmarTrend(R) - Tue Jul 29, 5:03PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $94.00 to a high of $102.27. Yesterday, the shares gained 8.1%, which took the trading range above the 3-day high of $94.67 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
United Therapeutics Corporation Reports Second Quarter 2014 Financial Results
PR Newswire - Tue Jul 29, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2014.
United Therapeutics Corporation To Announce Second Quarter 2014 Financial Results Before Market Open On Tuesday, July 29, 2014
PR Newswire - Tue Jul 22, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its second quarter 2014 financial results before market open on Tuesday, July 29, 2014.
Supernus Up on Non-Dilutive Royalty Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 3:43PM CDT
Supernus Pharmaceuticals, Inc.'s (SUPN) inked a non-dilutive royalty deal worth $30 million with HealthCare Royalty Partners.
Pluristem Initiates Trial in South Korea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 5:00PM CDT
Pluristem Therapeutics Inc. (PSTI) announced that it has initiated a phase II trial in South Korea to evaluate PLacental eXpanded cells for the treatment of intermittent claudication.
Supernus to Receive $30 Million in Non-Dilutive Royalty Deal
GlobeNewswire - Tue Jul 08, 6:30AM CDT
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced the execution of a royalty acquisition agreement ("Agreement"
with HealthCare Royalty Partners ("HC Royalty" . Per the Agreement, HC Royalty will make a $30 million cash payment to Supernus in consideration for acquiring from Supernus certain royalty and milestone rights related to the commercialization of Orenitram(TM) (treprostinil) Extended-Release Tablets by Supernus' partner United Therapeutics Corporation. Supernus will retain full ownership of the Royalty Rights after a certain threshold has been reached per the terms of the Agreement. Clinical Trial Update, Recommendations for Approval, Share Repurchase Programs, and Closing of Public Offering - Analyst Notes on Medtronic, Regeneron, Lilly, United Therapeutics and Receptos
PR Newswire - Wed Jul 02, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Eli Lilly and Company (NYSE: LLY), United Therapeutics Corporation (NASDAQ: UTHR) and Receptos Inc. (NASDAQ: RCPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4341-100free.
After Yesterday's Rally of 1.61% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jun 27, 4:57PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $88.05 to a high of $91.30. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $90.30 on volume of 778,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of United Therapeutics to Potentially Pullback after Yesterday's 1.61% Rise
Comtex SmarTrend(R) - Fri Jun 27, 4:56PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $88.05 to a high of $91.30. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $90.30 on volume of 778,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Today's Top Biotech Stocks: Bristol-Myers Squibb, United Therapeutics and Vertex Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Fri Jun 27, 8:11AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb , United Therapeutics and Vertex Pharmaceuticals . Bristol-Myers is a fountain of good news this morning Shares of...
United Therapeutics Announces Additional $500 Million Share Repurchase Program
PR Newswire - Fri Jun 27, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to an additional $500 million of the company's common stock. This program will become effective on August 1, 2014, and will remain open for up to one year. Purchases may be made in the open market or in privately negotiated transactions from time to time as determined by United Therapeutics' management and in accordance with the requirements of the U.S. Securities and Exchange Commission.
Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global
Health Care Sector Stocks Technical Analysis -- Research on United Therapeutics, IsoRay, Bruker, and Affymetrix
PR Newswire - Mon Jun 23, 6:50AM CDT
On Friday, June 20, 2014, the NASDAQ Composite ended at 4,368.04, up 0.20%, the Dow Jones Industrial Average finished the session at 16,947.08, up 0.15% and the S&P 500 closed at 1,962.87, up 0.17%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.84% higher at 702.66, and the index has advanced 3.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: United Therapeutics Corp. (NASDAQ: UTHR), IsoRay Inc. (NYSE MKT: ISR), Bruker Corp. (NASDAQ: BRKR) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on UTHR, ISR, BRKR and AFFX can be downloaded upon signing up at:
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into United Therapeutics Corporation Regarding Possible Breaches of Fiduciary Duty
Business Wire - Thu Jun 19, 12:18PM CDT
Levi & Korsinsky, LLP is investigating United Therapeutics Corporation (Nasdaq:UTHR) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company.
After Yesterday's Decline of 4.59%, United Therapeutics Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 17, 4:30PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $86.07 to a high of $90.55. Yesterday, the shares fell 4.6%, which took the trading range below the 3-day low of $89.24 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
United Therapeutics Falls 4.59% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 17, 4:30PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $86.07 to a high of $90.55. Yesterday, the shares fell 4.6%, which took the trading range below the 3-day low of $89.24 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
